85. Idiopathic interstitial pneumonia
514 clinical trials,   377 drugs   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03832946
(ClinicalTrials.gov)
February 19, 20194/2/2019A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 WeeksIdiopathic Pulmonary Fibrosis (IPF)Drug: TD139;Drug: PlaceboGalecto Biotech ABSyneos HealthRecruiting40 YearsN/AAll450Phase 2United States;Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom
2NCT02257177
(ClinicalTrials.gov)
September 201429/9/2014RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF PatientsA Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Inhaled TD139;Drug: PlaceboGalecto Biotech ABNULLCompleted45 Years85 YearsAll60Phase 1;Phase 2United Kingdom